877402-85-2 Usage
Chemical Structure
A unique structure containing a fluorine-substituted pyrazolodiazepinol core.
Therapeutic Applications
Potential treatment for various neurological and psychiatric disorders.
Anxiolytic Effects
Preliminary evaluations have shown promise as an anxiolytic (anti-anxiety) agent.
Antidepressant Properties
The compound has demonstrated potential as an antidepressant in early studies.
Cognitive Enhancer
It has been studied for its possible effects on cognitive enhancement.
Alcohol Addiction Treatment
Research into its potential use in treating alcohol addiction is ongoing.
Ongoing Research
Further studies are being conducted to explore the pharmacological properties and potential therapeutic uses of 2-(TRIFLUOROMETHYL)-7,8-DIHYDRO-6H-PYRAZOLO[1,5-A][1,4]DIAZEPIN-4-OL.
Medicinal Chemistry Value
Holds promise as a versatile and potentially valuable chemical entity in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 877402-85-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,4,0 and 2 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 877402-85:
(8*8)+(7*7)+(6*7)+(5*4)+(4*0)+(3*2)+(2*8)+(1*5)=202
202 % 10 = 2
So 877402-85-2 is a valid CAS Registry Number.
877402-85-2Relevant academic research and scientific papers
FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
-
Page/Page column 64, (2008/06/13)
The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
